SNAP-8 vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- SNAP-8 is a synthetic octapeptide cosmetic ingredient that reduces the depth of expression lines and wrinkles by competitively inhibiting the SNARE complex involved in acetylcholine release at neuromuscular junctions, providing a topical 'Botox-like' effect.
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- N/A — topical application; local effect duration depends on formulation
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 3–10% concentration in formulation
- 10 mg per day
- Frequency
- 1–2x daily
- Daily for 10–30 days
- Key Benefits
- Reduces depth of dynamic expression wrinkles
- Smooths forehead lines, crow's feet, glabellar lines
- Non-invasive topical Botox alternative
- Can be incorporated into serums, creams, eye contour products
- Reduces muscle contraction without paralysis
- Improves skin texture and firmness over time
- Complements other anti-aging peptides (Argireline, Matrixyl)
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Generally excellent tolerability
- Rare: mild redness in sensitive individuals
- Not suitable for injection (topical use only)
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —